UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

UCSF’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health.

The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma, following 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

Thomas G. Martin, MD, discusses the patient population of the phase 2 CARTITUDE-1 study in relapsed/refractory multiple myeloma.

Thomas G. Martin, MD, discusses some of the exciting clinical trials open at UCSF Helen Diller Family Comprehensive Cancer Center in multiple myeloma, especially for those in the relapsed/refractory setting.

Shumei Kato, MD, discusses the characterization of BRAF mutations in oncology.

Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.

Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers ​to use throughout the therapeutic process.

Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.

The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.

Nina Shah, MD, discusses key findings from the phase 2 KarMMA trial in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

Acquired resistance to endocrine therapy has presented challenges for patients with hormone receptor–positive breast cancer.

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.

Thomas G. Martin, MD, discusses the latest news in frontline, early relapsed, and heavily pretreated multiple myeloma, including the growing promise of quadruplets, emerging targets beyond BCMA, and the potential emergence of quadruplets, venetoclax, and antiviral therapy in amyloidosis.

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Nina Shah, MD, discusses potential future directions with CAR T-cell therapy in multiple myeloma.

Nina Shah, MD, discusses the clinical significance of idecabtagene vicleucel for the treatment of patients with multiple myeloma.